[go: up one dir, main page]

WO2006050041A3 - Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis - Google Patents

Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis Download PDF

Info

Publication number
WO2006050041A3
WO2006050041A3 PCT/US2005/038817 US2005038817W WO2006050041A3 WO 2006050041 A3 WO2006050041 A3 WO 2006050041A3 US 2005038817 W US2005038817 W US 2005038817W WO 2006050041 A3 WO2006050041 A3 WO 2006050041A3
Authority
WO
WIPO (PCT)
Prior art keywords
reducing
brain inflammation
methods
promoting neurogenesis
inhibiting brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/038817
Other languages
French (fr)
Other versions
WO2006050041A2 (en
Inventor
Beka Solomon
Vered Lavie
Maria Becker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of WO2006050041A2 publication Critical patent/WO2006050041A2/en
Publication of WO2006050041A3 publication Critical patent/WO2006050041A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The use of a phage displaying the amino acid sequence EFRH as an epitope of amyloid beta or displaying a molecule having the antigen binding portion of an antibody specific for the EFRH sequence in a method for reducing or inhibiting brain inflammation or in a method for promoting neurogenesis following the onset of neurodegeneration in a neurodegenerative disease or disorder which involves the pathological effects of amyloid beta by active or passive immunotherapy.
PCT/US2005/038817 2004-10-28 2005-10-27 Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis Ceased WO2006050041A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62267904P 2004-10-28 2004-10-28
US60/622,679 2004-10-28

Publications (2)

Publication Number Publication Date
WO2006050041A2 WO2006050041A2 (en) 2006-05-11
WO2006050041A3 true WO2006050041A3 (en) 2006-07-27

Family

ID=36061399

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/038817 Ceased WO2006050041A2 (en) 2004-10-28 2005-10-27 Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis

Country Status (1)

Country Link
WO (1) WO2006050041A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9580493B2 (en) 2011-06-23 2017-02-28 Biogen International Neuroscience Gmbh Anti-α synuclein binding molecules

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124076B2 (en) 2005-08-18 2012-02-28 Ramot At Tel Aviv University Ltd. Single chain antibodies against β-amyloid peptide
ATE541038T1 (en) * 2006-07-21 2012-01-15 Univ Ramot USE OF A PHAGE DISPLAYING A PEPTIDE OF AN ADHESION PROTEIN FOR THE TREATMENT OF A DISEASE ASSOCIATED WITH INTRACELLULAR FORMATION OF FIBRILLARY PROTEIN INCLUSIONS OR AGGREGATES
HRP20140049T1 (en) 2007-01-05 2014-02-28 University Of Zürich Anti-beta-amyloid antibody and uses thereof
HUE034512T2 (en) 2007-01-05 2018-02-28 Univ Zuerich Method of providing disease-specific binding molecules and targets
WO2010004434A2 (en) * 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
CA2746778C (en) 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
JP6147665B2 (en) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド Amyloid beta-binding protein
MA41115A (en) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh ALZHEIMER'S DISEASE TREATMENT PROCESS
HUE061510T2 (en) 2017-08-22 2023-07-28 Biogen Ma Inc Medicines containing anti-beta amyloid antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074243A2 (en) * 2001-03-15 2002-09-26 Ramot At Tel Aviv University Ltd. Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074243A2 (en) * 2001-03-15 2002-09-26 Ramot At Tel Aviv University Ltd. Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
FRENKEL D ET AL: "Generation of anti-beta-amyloid antibodies via phage display technology", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 22, no. 19, 23 June 2004 (2004-06-23), pages 2505 - 2508, XP004515471, ISSN: 0264-410X *
FRENKEL D ET AL: "Generation of auto-antibodies towards Alzheimer's disease vaccination", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 17-19, 21 March 2001 (2001-03-21), pages 2615 - 2619, XP004231088, ISSN: 0264-410X *
FRENKEL D ET AL: "N-TERMINAL EFRH SEQUENCE OF ALZHEIMER'S BETA-AMYLOID PEPTIDE REPRESENTS THE EPITOPE OF ITS ANTI-AGGREGATING ANTIBODIES", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, vol. 88, 1998, pages 85 - 90, XP001001343, ISSN: 0165-5728 *
FRENKEL D ET AL: "Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 21, no. 11-12, 7 March 2003 (2003-03-07), pages 1060 - 1065, XP004404279, ISSN: 0264-410X *
FRENKEL D ET AL: "TOWARDS ALZHEIMER'S BETA-AMYLOID VACCINATION", BIOLOGICALS, ACADEMIC PRESS LTD., LONDON, GB, vol. 29, no. 3/4, September 2001 (2001-09-01), pages 243 - 247, XP001156783, ISSN: 1045-1056 *
FRENKEL DAN ET AL: "Immunization against Alzheimer 's.beta.- amyloid plaques via EFRH phage administration", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 97, no. 21, 10 October 2000 (2000-10-10), pages 11455 - 11459, XP002180061, ISSN: 0027-8424 *
HAUGHEY NORMAN J ET AL: "Disruption of neurogenesis by beta-amyloid peptide in experimental models of Alzheimer's disease", DEVELOPMENTAL BRAIN RESEARCH, vol. 134, no. 1-2, 31 March 2002 (2002-03-31), & 4TH BRAIN RESEARCH INTERACTIVE SYMPOSIUM ON STEM CELLS IN THE MAMMALIAN BRAIN; SAN DIEGO, CA, USA; NOVEMBER 08-10, 2001, pages A39, XP009064418, ISSN: 0165-3806 *
LAVIE VERED ET AL: "EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials.", JOURNAL OF MOLECULAR NEUROSCIENCE : MN. 2004, vol. 24, no. 1, 2004, pages 105 - 113, XP009064346, ISSN: 0895-8696 *
PRINZ D M ET AL: "Two different methods result in the selection of peptides that induce a protective antibody response to Neisseria meningitidis serogroup C", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 285, no. 1, 1 February 2004 (2004-02-01), pages 1 - 14, XP004489661, ISSN: 0022-1759 *
SOLOMON B ET AL: "GENERATION AND BRAIN DELIVERY OF ANTI-AGGREGATING ANTIBODIES AGAINST BETA-AMYLOID PLAQUES USING PHAGE DISPLAY TECHNOLOGY", JOURNAL OF NEURAL TRANSMISSION. SUPPLEMENTUM, VIENNA, AT, vol. 62, no. SUPPL, 2002, pages 321 - 325, XP009041477, ISSN: 0303-6995 *
SOLOMON B ET AL: "VACCINATION FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE", DRUGS OF TODAY / MEDICAMENTOS DE ACTUALIDAD, J.R. PROUS SS.A. INTERNATIONAL PUBLISHERS, ES, vol. 36, no. 9, September 2000 (2000-09-01), pages 655 - 663, XP001030591, ISSN: 0025-7656 *
SOLOMON B: "Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease", DNA AND CELL BIOLOGY, NEW YORK, NY, US, vol. 20, no. 11, November 2001 (2001-11-01), pages 697 - 703, XP002236936, ISSN: 1044-5498 *
SOLOMON B: "S2-04-03 EFRH immunization restored cognitive functions of HAPP transgenic mice model of Alzheimer's disease", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, vol. 25, July 2004 (2004-07-01), pages S30, XP004624713, ISSN: 0197-4580 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9580493B2 (en) 2011-06-23 2017-02-28 Biogen International Neuroscience Gmbh Anti-α synuclein binding molecules

Also Published As

Publication number Publication date
WO2006050041A2 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
WO2006050041A3 (en) Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis
WO2006066049A3 (en) Humanized antibodies that recognize beta amyloid peptide
WO2005103081A3 (en) Human monoclonal antibodies against cd20
WO2008150946A8 (en) HUMANIZED ANTIBODIES WHICH BIND TO Aβ (1-42) GLOBULOMER AND USES THEREOF
EP2650308A3 (en) Use of anti-amyloid beta antibody in ocular diseases
WO2007064972A3 (en) Monoclonal antibodies against amyloid beta protein and uses thereof
WO2009048539A3 (en) Use of anti-amyloid beta antibody in ocular diseases
WO2004108895A3 (en) Humanized antibodies that recognize beta amyloid peptide
WO2013043933A3 (en) Cd27l antigen binding proteins
WO2004106380A3 (en) Human-anti-human cd3 binding molecules
GEP20125385B (en) Antibodies directed against amyloid-beta peptide and methods using same
EP2037961A4 (en) Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
WO2010057882A3 (en) Composition for producing anti-amyloid beta peptide antibodies with d-peptides
WO2004080419A3 (en) Humanized antibodies that recognize beta amyloid peptide
IL197459A0 (en) Humanized proteins, including antibodies and methods for producing the same
MX356800B (en) Humanized tau antibody.
EA201270813A1 (en) ANTIBODIES TO N3pGlu BETA AMYLOID PEPTIDE AND THEIR APPLICATION
WO2009083009A3 (en) Monoclonal antibodies against cd32b
WO2006066104A3 (en) Stilbene derivatives and their use for binding and imaging amyloid plaques
IL188592A0 (en) Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
WO2006099875A8 (en) Antibodies against cd38 for treatment of multiple myeloma
CR9512A (en) METHODS FOR THE TREATMENT OF BRAIN TUMORS WITH ANTIBODIES
WO2012009442A3 (en) Anti-addl monoclonal antibody and uses thereof
WO2006096489A3 (en) Anti-m-csf antibody compositions having reduced levels of endotoxin
HK1215673A1 (en) A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05824344

Country of ref document: EP

Kind code of ref document: A2